Conference Coverage Videos
Complete Conference Coverage
First-line treatment with nivolumab was not superior to investigator's choice of platinum-based doublet chemotherapy for progression-free survival.
Treatment with a full-dose regimen consisting of an anthracycline plus ifosfamide administered for 3 courses prior to surgery improves relapse-free and overall survival.
Treatment with atezolizumab resulted in a statistically significant and clinically relevant improvement in overall survival.
Maintenance therapy with niraparib significantly prolongs progression-free survival for all study populations of patients with recurrent ovarian cancer.
Adjuvant treatment with sunitinib prolonged disease-free survival, and was associated with a manageable safety profile.
Adjuvant treatment with ipilimumab significantly improved overall survival among patients with high-risk, stage III melanoma.
Adding ribociclib to letrozole is well tolerated, and significantly improves progression-free survival.
Dabrafenib is active and well-tolerated among patients with BRAF V600 mutation-positive pediatric low-grade glioma.
PD-L1 inhibition with durvalumab is associated with encouraging overall survival rates in pretreated HNSCC.
A 1-day, 3-drug, fosaprepitant-containing regimen is efficacious for preventing chemotherapy-induced nausea and vomiting.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Insurance Plans Dropping Coverage of FDA-approved BRCA Diagnostic Test
- The Undetermined Role of Sunscreen in Skin Cancer Prevention
- Lartruvo (Olaratumab) Offers New Promise for Patients With Soft Tissue Sarcoma
- Genomic Information and the Future of Health Care
- Landmark Approval for First-line Sarcoma Therapy
- Tivozanib Shows Antitumor Activity in Metastatic Soft Tissue Sarcoma
- FDA Approves Pembrolizumab for PD-L1-expressing Metastatic NSCLC
- Enzalutamide Prescribing Info Updated To Include New TERRAIN Data
- Doxorubicin-based Perioperative Therapy Recommended in Gastric Cancer
- Sorafenib Linked With Higher Adverse Event Risk